No Data
No Data
shandong wit dyne health (000915.SZ): Current products include probiotic powder, compound DHA algae oil droplets, children's biological toothpaste
Gelonghui September 5th | Shandong Wit Dyne Health (000915.SZ) stated on the investor interaction platform that Dyne Pharmaceuticals adopts category extension strategy in children's medicine products, continuously enriching the children's medicine product series based on the main product 'Yikexin' vitamin AD drops. In addition to 'Yikexin', the current products also include Yidexin, Dyne iron, Dyne calcium, Dyne zinc, oral rehydration salt powder, children's ibuprofen suppositories, hydrochloride tomoxetine oral solution and desloratadine oral solution. In terms of children's health products, the brand extension strategy is adopted, utilizing the extensive influence of 'Yikexin' to build 'Yikexin' children's nutritional products,
Shandong Wit Dyne Health (000915.SZ): The price increase of Vitamin A has little impact on the company.
On September 5th, Guolonghui reported that Shandong Wit Dyne Health (000915.SZ) stated on the investor interaction platform that the raw material supply of the company's vitamin AD drops is stable, and the price increase of vitamin A has little effect on the company.
Shandong Wit Dyne Health (000915.SZ): No plans for product price increases or mergers and acquisitions at this time.
On August 1st, Gelunhui reported that Shandong Wit Dyne Health (000915.SZ) stated on the investor interaction platform that the company has developed a core marketing strategy of "expert authority recommendation, convenient purchasing channels, and professional category education", and has formed academic promotion, business and retail, and new retail teams to sell products nationwide. The company currently has no plans to raise product prices or engage in mergers and acquisitions.
Shandong Wit Dyne Health: Summary of Half-Year Report in 2024.
Shandong Wit Dyne Health: Half-year report for the year 2024.
Shandong Wit Dyne Health (000915.SZ): Plans to distribute 10 dividends of 5 yuan for equity in mid-2024.
On July 31st, Gelunhui reported that Shandong Wit Dyne Health (000915.SZ) announced its mid-term profit distribution plan for 2024: Based on the total share capital of 234,331,485 shares as of June 30, 2024, the company will distribute cash dividends of RMB 5 per 10 shares (including tax) to all shareholders without bonus shares, nor increasing share capital through public reserves.
No Data